Comparative Effectiveness and Safety of LAMA-LABA Inhalers in Chronic Obstructive Pulmonary Disease
Vergleichende Wirksamkeit und Sicherheit von LAMA-LABA-Inhalatoren bei chronisch obstruktiver Lungenerkrankung
JAMA Internal Medicine · 01.04.2026 · 186 (4) · 456
DOI: 10.1001/jamainternmed.2025.8087 ↗Auf einen Blick
In einer Beobachtungsstudie war Umeclidinium-Vilanterol mit weniger moderaten oder schweren COPD-Exazerbationen verbunden als Glycopyrrolat-Formoterol und Tiotropium-Olodaterol. Bei anderen Endpunkten zeigten sich ähnliche Risiken.
Fragestellung
Wie unterscheiden sich Wirksamkeit und Sicherheit von Umeclidinium-Vilanterol, Glycopyrrolat-Formoterol und Tiotropium-Olodaterol bei COPD?
Methode
Beobachtungsstudie mit aktivem Vergleich; Claims-Daten; neu behandelte Patient:innen ≥40 Jahre; Propensity-Score-Matching 1:1; Analyse Juli bis August 2025.
Ergebnisse
9479 gematchte Paare Umeclidinium-Vilanterol vs Glycopyrrolat-Formoterol, 9598 Tiotropium-Olodaterol vs Glycopyrrolat-Formoterol, 36 740 Umeclidinium-Vilanterol vs Tiotropium-Olodaterol. HR 0,86; 95 %-KI 0,81–0,91; NNT 17. HR 0,97; 95 %-KI 0,94–0,99; NNT 100. HR 0,94; 95 %-KI 0,89–1,00.
Schlussfolgerung der Autor:innen
Die Autor:innen berichten, dass Umeclidinium-Vilanterol mit besseren klinischen Ergebnissen als die beiden anderen Therapien assoziiert war.
Kernaussagen
- Weniger Exazerbationen mit Umeclidinium-Vilanterol
- Kein Unterschied bei MACE, HWI oder Pneumoniehospitalisierung
- Dreifacher Vergleich bei neuen Nutzer:innen von LAMA-LABA
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Vergleichsstudie in der Zeitschrift JAMA Internal Medicine, erschienen am 01.04.2026. Verfasst von Gerard T Portela und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Muscarinic Antagonists, Bronchodilator Agents, Adrenergic beta-2 Receptor Agonists. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: COPD
Abstract (Originalsprache)
Importance Dual bronchodilator therapy with a long-acting muscarinic antagonist (LAMA) and a long-acting β 2 -agonist (LABA) is recommended for most patients with symptomatic chronic obstructive pulmonary disease (COPD). Fixed-dose LAMA-LABA therapies are available in metered-dose, dry powder, and soft mist inhalers. However, metered-dosed inhalers are associated with greater greenhouse gas emissions than either dry powder or soft mist inhalers, and questions persist about potential intraclass differences among LAMA-LABAs given variability in their active ingredients, dosing schedules, and delivery devices.
Objective
To evaluate the comparative effectiveness and safety of once-daily umeclidinium-vilanterol dry powder inhalers, twice-daily glycopyrrolate-formoterol metered-dosed inhalers, and once-daily tiotropium-olodaterol soft mist inhalers. Design, Setting, and Participants This observational active-comparator study analyzed claims of patients (≥40 years) newly treated with LAMA-LABA inhalers and continuously enrolled in a large commercial health insurance or Medicare Advantage plan during the 183-day baseline period. Patients were propensity score matched 1:1 into 3 cohorts with index dates ranging from May 1, 2016, to February 28, 2025. Data were analyzed from July to August 2025. Exposures Patients treated with umeclidinium-vilanterol, glycopyrrolate-formoterol, or tiotropium-olodaterol fixed-dose inhalers. Main Outcomes and Measures Time to the first moderate or severe COPD exacerbation, major adverse cardiovascular event, urinary tract infection, and pneumonia hospitalization.
Results
The cohorts included 9479 matched pairs of patients receiving umeclidinium-vilanterol vs glycopyrrolate-formoterol (mean age, 68.9 [SD, 9.0] years; 10 319 women [54.4%]; 8636 men [45.6%]), 9598 receiving tiotropium-olodaterol vs glycopyrrolate-formoterol (mean age, 69.2 [SD, 8.7] years; 10 513 women [54.8%]; 8680 men [45.2%]), and 36 740 receiving umeclidinium-vilanterol vs tiotropium-olodaterol (mean age, 71.5 [SD, 8.4] years; 39 429 women [53.7%]; 34 044 men [46.3%]). Umeclidinium-vilanterol was associated with a 14% lower hazard of a first moderate or severe COPD exacerbation than glycopyrrolate-formoterol (hazard ratio [HR], 0.86; 95% CI, 0.81-0.91; number needed to treat [NNT], 17) and was associated with a 3% lower hazard than tiotropium-olodaterol (HR, 0.97; 95% CI, 0.94-0.99; NNT, 100). Tiotropium-olodaterol was associated with a 6% lower hazard of a first moderate or severe COPD exacerbation than glycopyrrolate-formoterol (HR, 0.94; 95% CI, 0.89-1.00). Similar risks of first major adverse cardiovascular event, urinary tract infection, and pneumonia hospitalization were observed among patients in all 3 cohorts. Conclusions and Relevance This cohort study found that umeclidinium-vilanterol was associated with improved clinical outcomes compared with glycopyrrolate-formoterol and tiotropium-olodaterol. Patients, prescribers, and health systems may consider once-daily umeclidinium-vilanterol dry powder inhalers over alternatives among new users of LAMA-LABA therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
- Harvard Medical School, Boston, Massachusetts.
- Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Quebec, Canada.
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
- Now at the Division of Pulmonary, Critical Care, Sleep Medicine, Clinical Immunology and Allergy, Department of Medicine, University of California, Los Angeles.
Zitieren
APA
Portela, G. T., Wang, S. V., Suissa, S., & Feldman, W. B. (2026). Comparative Effectiveness and Safety of LAMA-LABA Inhalers in Chronic Obstructive Pulmonary Disease. JAMA Internal Medicine, 186(4), 456. https://doi.org/10.1001/jamainternmed.2025.8087
Vancouver
Portela GT, Wang SV, Suissa S, Feldman WB. Comparative Effectiveness and Safety of LAMA-LABA Inhalers in Chronic Obstructive Pulmonary Disease. JAMA Internal Medicine. 2026;186(4):456. doi:10.1001/jamainternmed.2025.8087
BibTeX
@article{Portela2026,
author = {Portela, Gerard T and Wang, Shirley V and Suissa, Samy and Feldman, William B},
title = {Comparative Effectiveness and Safety of LAMA-LABA Inhalers in Chronic Obstructive Pulmonary Disease},
journal = {JAMA Internal Medicine},
year = {2026},
volume = {186},
number = {4},
pages = {456},
doi = {10.1001/jamainternmed.2025.8087}
}
EUVIMED